Serum IL-17A in Newly Diagnosed Treatment-Naive Patients with Ulcerative Colitis Reflects Clinical Disease Severity and Predicts the Course of Disease
| Autor: | Lukas Van Oudenhove, Rahil Dahlén, Mary Jo Wick, Hans Strid, Åsa Sjöling, Stefan Isaksson, Lena Öhman, Henrik Sjövall, Magnus Simren |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Cross-sectional study Enzyme-Linked Immunosorbent Assay Disease Severity of Illness Index Gastroenterology Interferon-gamma Internal medicine Severity of illness medicine Humans Immunology and Allergy Prospective Studies Intestinal Mucosa Colitis Prospective cohort study Interleukin-13 business.industry Interleukin-17 Case-control study Prognosis medicine.disease Ulcerative colitis Cross-Sectional Studies Case-Control Studies Colitis Ulcerative Female Calprotectin business Biomarkers Follow-Up Studies |
| Zdroj: | Inflammatory Bowel Diseases. 19:2433-2439 |
| ISSN: | 1078-0998 |
| DOI: | 10.1097/mib.0b013e3182a563cb |
| Popis: | Background The clinical course of ulcerative colitis (UC) is unpredictable. The need for reliable biomarkers to reflect disease severity and predict disease course is therefore large. We investigated whether cytokines in mucosal tissue and serum reflect clinical disease severity at the onset of UC and predict the future disease course. Methods We prospectively monitored 102 patients from the onset of UC during 3 years, and they were followed up yearly for clinical and biochemical disease severity. Rectal biopsies were obtained from healthy controls and patients with UC. Serum and stool samples were obtained from patients with UC. Total mRNA from biopsies was analyzed with real-time PCR. Cytokine levels in serum were determined using Luminex or ELISA. Results Mucosal mRNA expression of IL-17A was 99.8 times higher while IFN-γ and IL-13 expression was increased 12.4 and 6.7 times, respectively, in patients relative to controls. Serum IL-17A correlated with clinical disease severity at the onset. Also, contrary to a number of other parameters, serum IL-17A at the onset predicted the clinical and biochemical course of the disease, as reflected by the Mayo score, number × severity of flares, and fecal calprotectin levels, respectively, during 3 years after the onset of the disease. None of these associations were found with mucosal cytokines at the onset. Conclusions Serum IL-17A levels of treatment-naive patients with UC reflect clinical disease severity at the onset of the disease and also predicted the disease course over the following 3 years. Thus, serum IL-17A may be valuable in the clinical management of patients with UC at the onset of the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|